2 results match your criteria: "Experimental and Clinical Research Center at the Max- Delbrueck-Center for Molecular Medicine[Affiliation]"
BMC Cancer
August 2021
Research Group Translational Oncology, Experimental and Clinical Research Center at the Max- Delbrueck-Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany.
Background: Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas. In previous studies, we found a significant down regulation of the relevant enzyme ferrochelatase in gastrointestinal carcinomas leading to an accumulation of protoporphyrin-IX within the tumor cells. Recent studies showed that a novel anti-cancer drug, Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to ferrochelatase.
View Article and Find Full Text PDFBMC Cancer
March 2013
Experimental Clinical Research Center at the Max-Delbrueck-Center for Molecular Medicine, Charité Campus Buch, Lindenbergerweg 80, Berlin, 13125, Germany.
Background: We attempted to identify novel biomarkers and therapeutic targets for esophageal squamous cell carcinoma by gene expression profiling of frozen esophageal squamous carcinoma specimens and examined the functional relevance of a newly discovered marker gene, WDR66.
Methods: Laser capture microdissection technique was applied to collect the cells from well-defined tumor areas in collaboration with an experienced pathologist. Whole human gene expression profiling of frozen esophageal squamous carcinoma specimens (n = 10) and normal esophageal squamous tissue (n = 18) was performed using microarray technology.